Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05798845 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv4
  2. Primary completion date: Dec 2024 to Dec 31, 2026
    • Start date: Feb 20, 2023 to Feb 20, 2025
    • Study completion date: Dec 2025 to Dec 31, 2026
    v3
  3. Primary completion date: Feb 2024 to Dec 2024
    • Study completion date: Feb 2025 to Dec 2025
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized phase II trial is to explore the clinical efficacy, safety and feasibility of neoadjuvant immunotherapy plus radiotherapy compared with neoadjuvant immunotherapy plus chemotherapy in operable stage II-IIIA (N+) non small cell lung cancer (NSCLC) and the optimal radiotherapy pattern.
Trial Details
NCT Number NCT05798845
Lead Sponsor Shanghai Chest Hospital
Collaborators: Shanghai Junshi Bioscience Co., Ltd.
Conditions
(from sponsor)		 NSCLC
Enrollment 124 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov